B J Curry1, K Myers, P Hersey. 1. Oncology and Immunology Unit, Mater Misericordiae Hospital, Newcastle, and Sydney Melanoma Unit, Sydney, New South Wales, Australia.
Abstract
PURPOSE: Polymerase chain reaction (PCR) with tyrosinase and with MART-1 permits detection of small numbers of circulating melanoma cells (CMCs) in patients who have undergone surgical resection of localized disease. In a previous study, we showed that PCR with MART-1 had sensitivity and specificity similar to those of PCR with tyrosinase in terms of detection of CMCs but that PCR with MART-1 seemed to identify a different but overlapping subgroup of patients. In the current study, we examined the utility and prognostic significance of PCR with tyrosinase and with MART-1. PATIENTS AND METHODS: We analyzed the prognostic significance of the patterns of expression of tyrosinase and MART-1 in 186 patients followed sequentially before and after surgical removal of American Joint Committee on Cancer stage I, II, or III melanoma. RESULTS: PCR with tyrosinase and with MART-1 in the first 3 months after surgery identified 68.5% of 73 patients who developed recurrence in the 2-year period after surgery. Approximately 35% of patients with positive tests remained disease-free at 2-year follow-up. We found that patients with disseminated recurrence had a significantly lower incidence of MART-1-positive CMCs (16%) than of tyrosinase-positive CMCs (63%). Patients with locoregional metastases had CMCs that expressed tyrosinase and MART-1 at similar rates. These differences in expression of the markers in patients with disseminated recurrence were also associated with a much lower disease-free survival, in those who had CMCs that were positive for tyrosinase but negative for MART-1. The reverse applied in those with locoregional disease. CONCLUSION: These findings suggest that PCR with MART-1 and with tyrosinase identifies subgroups of patients who develop disseminated or locally recurrent metastases. We hypothesize that immune responses against MART-1 may reduce the establishment of disseminated metastases.
PURPOSE: Polymerase chain reaction (PCR) with tyrosinase and with MART-1 permits detection of small numbers of circulating melanoma cells (CMCs) in patients who have undergone surgical resection of localized disease. In a previous study, we showed that PCR with MART-1 had sensitivity and specificity similar to those of PCR with tyrosinase in terms of detection of CMCs but that PCR with MART-1 seemed to identify a different but overlapping subgroup of patients. In the current study, we examined the utility and prognostic significance of PCR with tyrosinase and with MART-1. PATIENTS AND METHODS: We analyzed the prognostic significance of the patterns of expression of tyrosinase and MART-1 in 186 patients followed sequentially before and after surgical removal of American Joint Committee on Cancer stage I, II, or III melanoma. RESULTS: PCR with tyrosinase and with MART-1 in the first 3 months after surgery identified 68.5% of 73 patients who developed recurrence in the 2-year period after surgery. Approximately 35% of patients with positive tests remained disease-free at 2-year follow-up. We found that patients with disseminated recurrence had a significantly lower incidence of MART-1-positive CMCs (16%) than of tyrosinase-positive CMCs (63%). Patients with locoregional metastases had CMCs that expressed tyrosinase and MART-1 at similar rates. These differences in expression of the markers in patients with disseminated recurrence were also associated with a much lower disease-free survival, in those who had CMCs that were positive for tyrosinase but negative for MART-1. The reverse applied in those with locoregional disease. CONCLUSION: These findings suggest that PCR with MART-1 and with tyrosinase identifies subgroups of patients who develop disseminated or locally recurrent metastases. We hypothesize that immune responses against MART-1 may reduce the establishment of disseminated metastases.
Authors: Sojun Hoshimoto; Mark B Faries; Donald L Morton; Tatsushi Shingai; Christine Kuo; He-Jing Wang; Robert Elashoff; Nicola Mozzillo; Mark C Kelley; John F Thompson; Jeffrey E Lee; Dave S B Hoon Journal: Ann Surg Date: 2012-02 Impact factor: 12.969
Authors: Christina L Roland; Merrick I Ross; Carolyn S Hall; Barbara Laubacher; Joshua Upshaw; Amber E Anderson; Anthony Lucci Journal: Melanoma Res Date: 2015-08 Impact factor: 3.599
Authors: Piotr Rutkowski; Zbigniew I Nowecki; Alexander C J van Akkooi; Jadwiga Kulik; Michej Wanda; Janusz A Siedlecki; Alexander M M Eggermont; Wlodzimierz Ruka Journal: Ann Surg Oncol Date: 2010-07-07 Impact factor: 5.344
Authors: Gary A Clawson; Eric Kimchi; Susan D Patrick; Ping Xin; Ramdane Harouaka; Siyang Zheng; Arthur Berg; Todd Schell; Kevin F Staveley-O'Carroll; Rogerio I Neves; Paul J Mosca; Diane Thiboutot Journal: PLoS One Date: 2012-07-19 Impact factor: 3.240
Authors: Giuseppe Palmieri; Sabrina M R Satriano; Mario Budroni; Antonio Cossu; Francesco Tanda; Sergio Canzanella; Corrado Caracò; Ester Simeone; Antonio Daponte; Nicola Mozzillo; Giuseppe Comella; Giuseppe Castello; Paolo A Ascierto Journal: BMC Cancer Date: 2006-11-15 Impact factor: 4.430
Authors: Hope C Ball; Mohammad Y Ansari; Nashrah Ahmad; Kimberly Novak; Tariq M Haqqi Journal: Connect Tissue Res Date: 2020-10-12 Impact factor: 3.417